Answers are grounded in this paper and cite their sources.
Abdominal aortic aneurysm is a life-threatening vascular disease lacking effective pharmacotherapies. This study aimed to investigate the protective effect of empagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, against angiotensin II (AngII)-induced AAA in ApoE −/− mice and explore the underlying mechanisms. Twelve-week-old male ApoE −/− mice were randomly divided into Control, AngII-induced AAA (AAA group), and empagliflozin-treated (Empa group, 3 mg/kg/day) groups. After 28 days, empagliflozin significantly reduced AAA incidence (26.6% vs. 73.3% in AAA group), decreased maximum abdominal aortic diameter, improved survival rate (86.7% vs. 73.3%, P = 0.0032), and reduced the rate of aortic rupture. At the vascular tissue level, empagliflozin reduced inflammatory cell infiltration, preserved medial elastic fiber integrity, and decreased the AngII-induced upregulation of MMP9 ( P = 0.0188) and MMP2 ( P = 0.0039) in aortic tissues. 16 S rRNA sequencing revealed that empagliflozin reshaped gut microbiota composition, increasing the abundance of Tenericutes at the phylum level and Sutterella , Allobaculum , Colinsella , and Pelomonas at the genus level, while decreasing Methylobacterium . Targeted LC–MS/MS analysis revealed empagliflozin-associated changes in fecal SCFAs and plasma TMAO, accompanied by reduced intestinal permeability and attenuation of aortic TLR4/NF-κB signaling. Moreover, empagliflozin improved intestinal barrier integrity by restoring villus structure, upregulating ZO-1 and Occludin expression (both mRNA and protein levels), and reducing plasma LPS concentration ( P < 0.0001). Gut microbiota depletion with antibiotics completely abolished the protective effects of empagliflozin, whereas fecal microbial transplantation from empagliflozin-treated mice recapitulated the beneficial effects, including reduced AAA incidence, attenuated vascular inflammation, and improved intestinal barrier function. Empagliflozin inhibits AngII-induced AAA formation and progression by regulating the gut microbiota-intestinal barrier axis, providing a novel preventive strategy for AAA.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: